On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Weekly Release  2003: Volume 7/ Issue 4 Article 3
Back to Table of Contents

Eurosurveillance, Volume 7, Issue 4, 23 January 2003

Citation style for this article: Harris J. Global Fund to fight AIDS, tuberculosis, and malaria makes progress. Euro Surveill. 2003;7(4):pii=2153. Available online:

Global Fund to fight AIDS, tuberculosis, and malaria makes progress

John Harris (, Public Health Laboratory Service Communicable Disease Surveillance Centre, London, England.

According to Richard Feacham Executive Director of the Global Fund (, the global HIV/AIDS pandemic is already worse than the Black Death, which raged in the mid 14th Century and is the largest catastrophe in recorded human history. The HIV/AIDS pandemic is not expected to peak until around 2050 or 2060. Feacham noted that India is currently on the same trajectory as Africa, but lagging 15 years behind. At present, there is nothing in place to alter the situation in India and the scale of the Indian epidemic will be 'staggering'.

Policies agreed by the Global fund on procurement of drugs used to treat HIV/AIDS have prompted some large pharmaceutical companies to widen the availability of discounted drugs. At the last Global Fund board meeting it was decided that any drugs purchased using money donated by the Global Fund had to fulfil three principles. Drugs purchased will be at the lowest cost, they must be of assured quality, and purchases must conform to national and international legal agreements. Low income countries would now have the ability not only to access discounted drugs from the richer countries, but also to buy generic drugs from middle income countries.

The response of some drug companies to the existence of the Global Fund has resulted in bigger discounting of drugs. For example, GlaxoSmithKline announced increased discounts on drugs, and wider inclusion so that all recipients of Global Fund finance would be able to take advantage of the discounts. This means discounted drugs will now be more widely available not only to the poorest nations, but also to some middle income countries.

The Global Fund was set up in 2001 with the purpose of attracting and distributing funds to projects aimed at reducing the burden of infectious disease. The main focus is HIV/AIDS, TB and Malaria. So far 2 billion dollars have been pledged. Global Fund money is already helping to increase the number of people with access to treatments for HIV.

Further information on featured stories and further details of the Global fund are available from the Global Fund newsletter the Global Fund Observer (GFO) at 

There is also a discussion forum for news and commentary on the Global Fund. At present there are over 2000 subscribers to the newsletter from over 100 countries.

back to top

Back to Table of Contents

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.